Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer

NCT07627620 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer

Interventions

DRUG: Camrelizumab
DRUG: Famitinib Malate
DRUG: Chemotherapy

Sponsor

Hunan Cancer Hospital